June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
C5 Contributes to Ocular Inflammation in Experimental Autoimmune Uveitis
Author Affiliations & Notes
  • Aixu Sun
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Ming Yuan
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Hua Yang
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Thomas Clayton MacPherson
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Adrianna Latuszek
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Henry Chen
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Ying Hu
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Jingtai Cao
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Carl Romano
    Ophthalmology, Regeneron Pharmaceutical Inc., Tarrytown, New York, United States
  • Footnotes
    Commercial Relationships   Aixu Sun, Regeneron Pharmaceutical Inc. (E); Ming Yuan, Regeneron Pharmaceutical Inc. (E); Hua Yang, Regeneron Pharmaceutical Inc. (E); Thomas MacPherson, Regeneron Pharmaceutical Inc. (E); Adrianna Latuszek, Regeneron Pharmaceutical Inc. (E); Henry Chen, Regeneron Pharmaceutical Inc. (E); Ying Hu, Regeneron Pharmaceutical Inc. (E); Jingtai Cao, Regeneron Pharmaceutical Inc. (E); Carl Romano, Regeneron Pharmaceutical Inc. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 536. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Aixu Sun, Ming Yuan, Hua Yang, Thomas Clayton MacPherson, Adrianna Latuszek, Henry Chen, Ying Hu, Jingtai Cao, Carl Romano; C5 Contributes to Ocular Inflammation in Experimental Autoimmune Uveitis. Invest. Ophthalmol. Vis. Sci. 2017;58(8):536.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Complement has been implicated in ocular inflammation. The present study was undertaken to evaluate the role of C5 in experimental autoimmune uveitis (EAU). We used both genetic (C5 KO, C3/C5 double KO mice), and pharmacologic (anti-C5 antibody) experimental approaches.

Methods : Adult C57BL/6J mice (n=25), C5 KO (n=13) and C3/C5 KO (n=8) mice (Regeneron Pharmaceuticals Inc.) were used. EAU was induced by subcutaneous injection of human interphotoreceptor retinoid-binding protein peptide (IRBP, New England Peptide) in complete Freund’s adjuvant and intraperitoneal injection of pertussis toxin. Anti-mouse C5 mAb or isotype control mAb was administered through S.C injections every 3 days from day 5 to 28 post-IRBP. The SPECTRALIS HRA+OCT was used to assess levels of inflammation on days -1, 7, 14, 21 and 28. All animals were euthanized on day 28 and eyes and blood recovered. Hemolysis assays were performed with the recovered serum to assess in vivo complement inhibition. Data were analyzed by ANOVA.

Results : Compared to wild type mice, inflammation incidence (30-50%) and vitreous cell cluster counts were significantly decreased in C5 KO mice (p<0.01). OCT scores in C5 KO mice also significantly reduced 50% at week 3 (p<0.0001). Interestingly, in C3/C5 double KO mice, there were significantly more vitreous cell clusters and higher disease scores on day 28 compared to wild type mice (p<0.05). In animals that received anti-C5 Ab (50mg/kg), inflammation incidence and vitreous cell clusters were significantly lower compared to either no treatment or isotype control on day 21 (p<0.01). At week 3 and 4, OCT scores in anti-C5 Ab (50mg/kg) group were significantly lower compared to no treatment or isotype control (p<0.0001). Hemolysis assays confirmed the inhibition by anti-C5 Ab at week 4.

Conclusions : Ocular inflammation due to EAU was mitigated by inhibiting C5 activity, either by genetic deletion or pharmacologic inhibition with a specific monoclonal antibody. These results indicate that C5 is a potential therapeutic target for autoimmune uveitis.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×